{"id":"doi:10.1136/bmj.p73","kind":"article","title":"Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns","authors":["Elisabeth Mahase"],"author_count":1,"year":2023,"published":"2023-01-11","venue":"BMJ","cited_by":43,"doi":"10.1136/bmj.p73","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1136/bmj.p73","archive_url":"https://space-kitty.com/papers/doi:10.1136/bmj.p73","updated":null,"pmid":"36631154","pmcid":null,"openalex_id":"W4315632151","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer's disease research and treatments"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}